GlassScriptPhysician profile
Anthony M Molodecki
NPI 1417020074
$2,678.77
in general payments reported to CMS, 2019-2025
21 companies · $538 in 2025
The $538 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $808 · 2022: $575 · 2023: $358 · 2024: $400 · 2025: $538.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,296.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,295.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $863.61 | 2021-2025 | Ams 700, Axonics |
| Axonics, INC. | $364.44 | 2021-2023 | Axonics |
| Sumitomo Pharma America, INC. | $258.74 | 2023-2025 | Orgovyx, Gemtesa |
| Endo Pharmaceuticals INC. | $255.61 | 2021-2024 | Xiaflex, Edex, Aveed |
| Abbvie INC. | $181.44 | 2021-2025 | |
| Astellas Pharma US INC | $161.40 | 2021-2023 | Myrbetriq |
| Endo USA, INC. | $157.49 | 2024-2025 | Xiaflex, Aveed |
| Janssen Biotech, INC. | $81.01 | 2021-2025 | Erleada |
| Bayer Healthcare Pharmaceuticals INC. | $77.53 | 2021-2024 | |
| Merck Sharp & Dohme LLC | $41.89 | 2022-2025 | Keytruda |
| Bluewind Medical | $38.82 | 2024 | Revi |
| Immunitybio, INC. | $28.59 | 2025 | |
| Progenics Pharmaceuticals, INC. | $24.75 | 2023 | Pylarify |
| Amgen INC. | $23.93 | 2021 | |
| Novartis Pharmaceuticals Corporation | $20.49 | 2025 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tolmar, INC. | $17.71 | 2025 | Eligard |
| Pfizer INC. | $17.61 | 2021 | |
| Myovant Sciences INC. | $17.34 | 2022 | |
| Urovant Sciences INC | $16.89 | 2022 | |
| Clarus Therapeutics INC. | $15.99 | 2021 | |
| Allergan, INC. | $13.49 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Molodecki listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.